| Target Price | $15.10 | 
| Price | $3.95 | 
| Potential | 
      
            
    
      
    
  282.18%
     register free of charge | 
| Number of Estimates | 3 | 
| 3 Analysts have issued a price target Sonoma Pharmaceuticals, Inc. 2026 .
        The average Sonoma Pharmaceuticals, Inc. target price is $15.10.
        This is 
       
    
      
    
  282.18%
     register free of charge 
                $15.54 
    
      
    
  293.42%
     register free of charge 
                $14.95 
    
      
    
  278.43%
     register free of charge | |
| A rating was issued by 7 analysts: 6 Analysts recommend Sonoma Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Sonoma Pharmaceuticals, Inc. stock has an average upside potential 2026 of 
       
    
      
    
  282.18%
     register free of charge | 
| Mar '25 | 2026 Estimates | |
|---|---|---|
| Revenue Million $ | 14.29 | 17.57 | 
| 12.17% | 22.98% | |
| Net Margin | -24.21% | -12.53% | 
| 36.27% | 48.25% | 
3 Analysts have issued a sales forecast Sonoma Pharmaceuticals, Inc. 2026 . The average Sonoma Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
3 Sonoma Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average Sonoma Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '25 | 2026 Estimates | |
|---|---|---|
| Earnings Per Share $ | -2.79 | -1.34 | 
| 73.78% | 51.97% | |
| P/E | negative | |
| EV/Sales | 0.17 | 
3 Analysts have issued a Sonoma Pharmaceuticals, Inc. forecast for earnings per share. The average Sonoma Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Sonoma Pharmaceuticals, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


